ABT-229 FOR POSTPRANDIAL DIGESTIVE SYMPTOMS ASSOCIATED WITH FUNCTIONAL DYSPEPSIA

ABT-229 用于治疗与功能性消化不良相关的餐后消化症状

• 批准号: 6276572
• 负责人: JAMES M GORDON
• 金额: $ 1.83万
• 依托单位: CASE WESTERN RESERVE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6276572
• 关键词: clinical research; drug screening /evaluation; gastrointestinal disorder chemotherapy; gastrointestinal sign /symptom; human subject; human therapy evaluation; macrolide antibiotics; placebos

Functional dyspepsia or nonulcer dyspepsia is an upper gastrointestinal disorder that is characterized by persistent or recurrent symptoms of upper abdominal discomfort which cannot be attributed to structural or biochemical abnormalities. Currently no definitive underlying pathophysiological mechanisms have been elucidated to explain this disorder and there is no conclusive evidence available identifying a definitive efficacious treatment regimen. ABT-229 is a novel macrolide with motilin agonist activity and devoid of any significant antibiotic activity. The objectives of this study are to assess the efficacy of ABT-229 compared to placebo for the treatment of postprandial digestive symptoms associated with functional dyspepsia and to assess the safety of ABT-229 in these patients.

功能性消化不良或非溃疡性消化不良是一种上消化道疾病， 一种以持续或复发的症状为特征的疾病， 上腹部不适，不能归因于结构或 生化异常 目前没有明确的基础 已经阐明了病理生理机制来解释这一点 目前还没有确凿的证据表明， 明确有效的治疗方案。 ABT-229是一种新型大环内酯类抗生素 具有胃动素激动剂活性且没有任何显著的抗生素 活动 本研究的目的是评估 ABT-229与安慰剂相比用于治疗餐后消化道疾病 与功能性消化不良相关的症状，并评估安全性 ABT-229在这些患者中的应用